No abstract

The aim of this work is to estimate patient doses from hybrid single-photon emission computed tomography (SPECT) and computed tomography (CT) procedures. The study involved all four SPECT-CT systems in Bulgaria. Effective dose was estimated for about 100 patients per system. Ten types of examinations were considered, representing all diagnostic procedures performed in the SPECT-CT systems. Effective doses from the SPECT component were calculated applying the ICRP 53 and ICRP 80 conversion coefficients. Computed tomography dose index and dose length product were retrospectively obtained from the archives of the systems, and effective doses from the CT component were calculated with CT-Expo software. Parallel estimation of CT component contribution with the National Radiological Protection Board (NRPB) conversion coefficients was performed where applicable. Large variations were found in the current practice of SPECT-CT imaging. Optimisation actions and diagnostic reference levels were proposed.

No abstract

No abstract

Positron emission tomography (PET) was installed for the first time in Bulgaria in 2009, and nowadays two hybrid PET-computed tomography (CT) systems are in operation. The aim of this work is to estimate patient doses from PET-CT procedures and to explore potential for optimisation. Data were retrospectively collected for 50 patients examined with the system Philips Gemini TF and for 58 patients examined with the system GE Discovery 600. Whole-body examinations with radiopharmaceutical (18)F-2-fluoro-2-deoxy-D-glucose (FDG) were performed on all patients. Patient effective doses from the CT component of the examination were calculated with CT Expo software and compared with doses estimated applying the National Radiological Protection Board (NRPB) conversion coefficients. Effective doses from the PET component were calculated applying the ICRP 80 conversion coefficients. For the first system, average effective doses from CT component were 8.0 and 8.9 mSv, applying CT Expo and NRPB coefficients, respectively, and 4.9 mSv from PET component. For the second system, the corresponding values were 7.8, 8.7 and 5.9 mSv. These results for patient effective doses are relatively lower or comparable to other similar surveys. Reasons for the observed differences are analysed and presented.